02592 撥康視雲－Ｂ
CLOUDBREAK-B
CLOUDBREAK-B
| Listing Date | 2025/07/03 Listed Today |
| Listing Price | 10.100 |
Quote
Subscription Result
- Subscription Rate78.78x
- Guarantee One Lot Size50 lot
- One Lot Success Rate5%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Cloudbreak Pharma Inc. is a clinical-stage ophthalmology biotechnology company dedicated to the development of various treatments. The Group have developed two proprietary technology platforms, namely, multi-kinase inhibitor and antibody-drug synergism platforms, designed for developing drug candidates targeting anterior and posterior ophthalmic diseases, respectively.
--
The Group have two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed, and its other drug candidates are in relatively earlier development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011. As of 18 June 2025, the Group had 60 granted patents and 168 pending patent applications worldwide.
--
The Group’s Core Product CBT-001 is indicated for the treatment of pterygium, and it have commenced phase 3 multi-regional clinical trial in the United States and China in June 2022 and September 2023 respectively for it. The Group’s Core Product CBT-009 is indicated for the treatment of juvenile myopia, and it have completed the phase 1/2 clinical trial in January 2023 and submitted the investigational new drug application to the United States Food and Drug Administration in July 2024 for it.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 60.58M shares |
| No. of International Offer Shares | 48.47M shares |
| No. of HK Offer Shares | 12.12M shares |
| Offer Price | $10.10 |
| Stock Code | 2592 |
| Sponsor(s) | CCB International Capital Limited, Huatai Financial Holdings (Hong Kong) Limited |
| Underwriter(s) | CCB International Capital Limited, Huatai Financial Holdings (Hong Kong) Limited, BOCI Asia Limited, BOCOM International Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited, China Industrial Securities International Capital Limited, CMBC Securities Company Limited, CMB International Capital Limited, First Shanghai Securities Limited, Fosun International Securities Limited, Huafu International Securities Limited, ICBC International Securities Limited, Livermore Holdings Limited, Patrons Securities Limited, Quam Securities Limited, Ruibang Securities Limited, Soliton Securities Limited, SPDB International Capital Limited, uSmart Securities Limited |
TIME TABLE
| Application Period | Jun 24 (Tue) - noon, Jun 27 (Fri) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jul 02 (Wed) |
| Result Announcement Date | On or before Jul 02 (Wed) |
| Result Announcement Date | On or before Jul 03 (Thu) |
| Dealings in Shares commence on | Jul 03, 2025. (Thu) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $10.10 |
| Capitalization | 8.47B |
| NAV / share ($) | $1.02 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 10.1, the net proceeds raised would be HKD 522.20M, of which |
| 62.4% : Clinical R&D activities registration filings and post-approval studies of Core Product, CBT-001 |
| 27.6% : Fund the continuing clinical R&D activities including costs and expenses of our R&D staffand R&D activities as well as registration filings of Core Product, CBT-009 |
| 5.5% : Funding the manufacturing facilities and commercialisation activities |
| 4.5% : Working capital |
IPO NEWS
| 03/07/2025 16:08 |
| {New Stock}CLOUDBREAK-B(02592) ends down 38.61% at HK$6.2 |
| 03/07/2025 09:20 |
| {New Stock}CLOUDBREAK-B(02592) opens down 5.94% at HK$9.5 |
| 02/07/2025 18:35 |
| {New Stock}CLOUDBREAK-B(02592) ends up 4.95% on grey market |
| 02/07/2025 16:20 |
| {New Stock}CLOUDBREAK-B up 7.92% at HK$10.9 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).